Myriad Genetics MYGN Hereditary Cancer — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Myriad Genetics’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's hereditary cancer — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Myriad Genetics's hereditary cancer — revenue?
- Myriad Genetics (MYGN) reported hereditary cancer — revenue of $96.8M in Q4 2025.
- How has Myriad Genetics's hereditary cancer — revenue changed year-over-year?
- Myriad Genetics's hereditary cancer — revenue increased by 2.5% year-over-year, from $94.4M to $96.8M.
- What is the long-term trend for Myriad Genetics's hereditary cancer — revenue?
- Over 2 years (2023 to 2025), Myriad Genetics's hereditary cancer — revenue has grown at a 6.6% compound annual growth rate (CAGR), from $327.8M to $372.4M.
- What does hereditary cancer — revenue mean?
- This metric represents the total revenue generated from molecular diagnostic testing services specifically focused on identifying hereditary cancer risks. It reflects the commercial performance of the company's core genetic screening portfolio. Tracking this revenue stream helps investors assess market demand for hereditary cancer diagnostics and the company's ability to maintain its competitive position in the precision medicine space.